Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
EBV-positive diffuse large B-cell lymphoma, not otherwise specified (EBV DLBCL-NOS), is an EBV-positive clonal B-cell lymphoid proliferation and circulating EBV-DNA is a great indicator for prognosis among EBV associated disease. In this retrospective study, we report 66 EBV DLBCL cases among 2137 DLBCL-NOS cases diagnosed from 2013 to 2021 (prevalence of 6.0%). After a median follow-up of 27 months, progression-free survival (PFS) and overall survival (OS) at 2 years were 39.5% ± 6.2% and 53.6% ± 6.4%, respectively. Multivariate analysis showed that only the biomarker of the positivity of post treatment EBV-DNA had a borderline correlation with shorter PFS and OS (PFS: P = 0.053; OS: P = 0.065). Patients were divided into three subgroups according to dynamic changes of EBV-DNA status: EBV-DNA persistently negative group, EBV-DNA persistently positive group, and EBV-DNA transformed from positive to negative group; among the three groups, patients of the persistently positive group had worst PFS and OS (P = 0.0527 and P = 0.0139, respectively). Decline in EBV copies correlated significantly with treatment response as well. In conclusion, circulating EBV-DNA level played a vital role in prognostic and monitoring marker for EBV DLBCL-NOS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00277-023-05260-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Longitudinal assessment of plasma EBV-DNA in non-endemic EBV-related nasopharyngeal cancer (NPC): the LEA study.
Eur J Cancer
August 2025
Immunohematology and Transfusion Medicine Service, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Background: Plasma Epstein Barr Virus (EBV)-DNA is an established biomarker for endemic EBV-related nasopharyngeal carcinoma (NPC). Its relevance in non-endemic regions is less understood. This study longitudinally assessed plasma EBV-DNA (LEA study) throughout the curative management of non-endemic EBV-related NPC to evaluate its prognostic value.
View Article and Find Full Text PDFApplication of circulating tumor DNA liquid biopsy in nasopharyngeal carcinoma: A case report and review of literature.
World J Clin Cases
July 2025
Department of Radiation Oncology, The First Hospital of China Medical University, Shenyang 110001, Liaoning Province, China.
Background: Circulating tumor DNA (ctDNA)-based liquid biopsy has been found to be effective for the detection of minimal residual disease and the evaluation of prognostic risk in various solid tumors, with good sensitivity and specificity for identifying patients at high risk of recurrence. However, use of its results as a biomarker for guiding the treatment and predicting the prognosis of nasopharyngeal carcinoma (NPC) has not been reported.
Case Summary: In this case study of a patient with stage IVb NPC, we utilized ctDNA as an independent biomarker to guide treatment.
Baseline total lesion glycolysis identifies high-risk patients with immunosuppressive signatures in early-stage natural killer/T-cell lymphoma.
Oncologist
June 2025
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Background: The post-treatment Deauville scale (DS) and circulating Epstein-Barr virus (EBV)-DNA were used for prediction of long-term remission in natural killer/T-cell lymphoma (NKTCL). However, the baseline biomarkers still remain lacking for clinical application. Here, we hypothesized that 18F-FDG PET/CT, as a measure of total tumor burden, would be a baseline biomarker to identify high-risk NKTCL patients.
View Article and Find Full Text PDFBiomarkers for nasopharyngeal carcinoma.
Clin Chim Acta
May 2025
Department of Laboratory Medicine, The Island Healthcare Complex-Macao Medical Center of Peking Union Medical College Hospital, 999078, Macao; Department of Laboratory Medicine, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing 100730,
Nasopharyngeal Carcinoma (NPC) is a malignant tumor that is highly prevalent in Southeast Asia, particularly in China and Indonesia. According to the World Health Organization's global cancer statistics in 2022, there were 120,434 new cases and 73,485 deaths from NPC. Risk factors contribute to NPC development including genetic factors, dietary habits, and Epstein-Barr virus (EBV) infection.
View Article and Find Full Text PDFPersonalising Nasopharyngeal Cancer: Systemic Therapy and Radiotherapy Treatment Volumes.
Semin Radiat Oncol
April 2025
Department of Head and Neck and Thoracic Cancers, Division of Radiation Oncology and Division of Medical Sciences, National Cancer Centre Singapore, Singapore.; Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore.. Electronic address:
Nasopharyngeal carcinoma (NPC) is sensitive to chemotherapy and radiotherapy, with current treatment recommendations largely based on TNM-stage. Radiotherapy remains the backbone of treatment for NPC. Over the past decades, the addition of concurrent chemotherapy to radiotherapy for early-stage disease, and the combination of induction chemotherapy (IC) or adjuvant chemotherapy (AC) with chemoradiotherapy vs chemoradiotherapy alone for advanced disease have led to substantial improvements in survival of patients with NPC.
View Article and Find Full Text PDF